Attainment of low-density lipoprotein cholesterol goals in statin treated patients: Real-world evidence from Australia.


Journal

Current problems in cardiology
ISSN: 1535-6280
Titre abrégé: Curr Probl Cardiol
Pays: Netherlands
ID NLM: 7701802

Informations de publication

Date de publication:
Jul 2022
Historique:
received: 18 10 2021
revised: 10 11 2021
accepted: 10 11 2021
pubmed: 25 11 2021
medline: 7 6 2022
entrez: 24 11 2021
Statut: ppublish

Résumé

Little is known about the attainment of low-density lipoprotein cholesterol (LDL-C) targets in patients treated with statins in Australian primary healthcare setting that are at increased risk of cardiovascular disease. A retrospective cohort study was conducted using data from electronic medical records of patients treated by general practitioners across Australia. LDL-C target attainment was defined as LDL-C levels ≤ 2 mmol/L for all risk groups, in line with Australian guidelines. Multivariable logistic regression was used to identify the factors associated with LDL-C target attainment. Overall, 61,407 patients were included in the analysis. The mean age was 65 years (± standard deviation [SD] 12.1); 52.0% were males.. Overall, the median LDL-C level was 2.3 mmol/L (IQR = 1.8 - 2.8) and 36.0% of the study population met therapeutic targets. Increased likelihood to achieve LDL-C targets was observed in patients diagnosed with type 2 diabetes (OR 2.07, 95% CI 1.92 - 2.24), stroke (OR = 1.58, 95% CI 1.39 - 1.79, P < 0.001) or chronic heart disease (OR = 1.67, 95% CI 1.55 - 1.81, P < 0.001). Patients diagnosed with dyslipidemia (OR = 0.59, 95% CI 0.55 - 0.64, P < 0.001), hypertension (OR = 0.91, 95% CI 0.83 - 1.00, P < 0.05) and current smokers (OR = 0.71, 95% CI 0.71 - 1.00, P < 0.05), were less likely to attain LDL-C targets, regardless of the type, intensity and length of use of the prescribed statin. Longer duration and higher intensity statin were associated with more patients achieving targeted LDL-C goal, however nearly two thirds of Australians still failed to achieve targeted outcome even after 24 months of statin therapy.

Identifiants

pubmed: 34818528
pii: S0146-2806(21)00276-0
doi: 10.1016/j.cpcardiol.2021.101068
pii:
doi:

Substances chimiques

Cholesterol, LDL 0
Hydroxymethylglutaryl-CoA Reductase Inhibitors 0

Types de publication

Journal Article Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

101068

Informations de copyright

Copyright © 2021 Elsevier Inc. All rights reserved.

Auteurs

Stella Talic (S)

School of Public Health and Preventive Medicine, Monash University, Melbourne, Australia. Electronic address: stella.talic@monash.edu.

Clara Marquina (C)

School of Public Health and Preventive Medicine, Monash University, Melbourne, Australia.

Ella Zomer (E)

School of Public Health and Preventive Medicine, Monash University, Melbourne, Australia.

Richard Ofori-Asenso (R)

School of Public Health and Preventive Medicine, Monash University, Melbourne, Australia.

Marjana Petrova (M)

School of Public Health and Preventive Medicine, Monash University, Melbourne, Australia.

Sandra Vargas-Torres (S)

School of Public Health and Preventive Medicine, Monash University, Melbourne, Australia.

Dina Abushanab (D)

School of Public Health and Preventive Medicine, Monash University, Melbourne, Australia; Pharmacy Department, Hamad Medical Corporation, Doha, Qatar.

Rory Wolfe (R)

School of Public Health and Preventive Medicine, Monash University, Melbourne, Australia.

Sean Lybrand (S)

Amgen Europe GmbH.

David Thomson (D)

Amgen Australia Pty Ltd.

Giles Stratton (G)

IQVIA Australia.

Danny Liew (D)

School of Public Health and Preventive Medicine, Monash University, Melbourne, Australia.

Zanfina Ademi (Z)

School of Public Health and Preventive Medicine, Monash University, Melbourne, Australia.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH